• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제29권2호
• /
• pp.187-191
• /
• 2007

An ameloblastoma is one of the most common odontogenic tumors. Ameloblastoma is cytologically a benign tumor, but is clinically characterized by infiltrative growth and high recurrency. The treatment of ameloblastoma has been controversial. The aim of this paper is to consider effectiveness of curettage and enucleation after SSRO in the small-sized multilocular intraosseous ameloblastomas that have been treated more frequently by radical treatment. They were radiographically characterized by the cortical bone that was expanded or eroded locally and histopathologically by solid multilocular ameloblastomas. It is considered that curettage and enucleation after SSRO and long-term follow-up enable the small-sized multilocular intraosseous ameloblastomas that were characterized by almost destroyed cancellous bone and expanded cortical bone to treat minimizing facial disfigurement and masticatory dysfunction and sociopsychological impact produced by radical treatment. We recommend that the small-sized multilocular intraosseous ameloblastomas without involvement to the surrounding soft tissues be first treated by curettage and enucleation after SSRO.

• 대한골관절종양학회지
• /
• 제9권1호
• /
• pp.77-83
• /
• 2003

공격성 섬유종증은 비교적 드문 연부 조직 종양이지만, 국소 증식 및 침윤성이 강한 종양으로 알려져 있다. 그렇지만 종양 증식에 관한 정확한 기전은 아직 보고되어 지지 않고 있다. 한편, 종양 억제 유전자 PTEN은 국소 침윤성과 전이를 보이는 여러 암 조직에서 발현의 감소 또는 돌연 변이가 보고되고 있다. 본 연구에서는 공격성 섬유종증에서 면역조직화학적 염색과 면역탁본법을 통해 종양 억제 유전자 PTEN의 발현의 양상을 알아보고자 하였다. 면역 탁본법과 면역조직화학적 염색상 PTEN의 발현은 정상 근막 조직에서는 균일하게 발현되었으나, 공격성 섬유종증 종양조직에서는 발현이 감소하였다. 공격성 섬유종증에서 PTEN발현의 감소는 급속한 증식과 재발 및 주위 조직의 침윤이 특징인 공격성 섬유종증의 병인에 관련이 있을 것으로 사료된다.

• Journal of Chest Surgery
• /
• 제30권10호
• /
• pp.1040-1043
• /
• 1997

식도암 .수술후 발생한 bronchiolitis obliterans organizing pneumonia환자 1례를 보고하고자 한다. 이 환자는 수술후 4일째부터 미열, 마른기침, 경미한 호흡곤란을 호소하였다 이때 촬영한 단순 흉부 사진과 흉부 컴퓨터 촬영상 폐양측에 반성(Patchy)침습소견이 나타났다. 고식적 치료에도 불구하고 경도의 백혈구 증다증과 함께 호흡기 증상은 더욱 악화되어 호흡부전의 소견을 보였다. 개흉적 폐생검을 실시하였으며, 병리조직검사 상 BOOP라는 진단을 얻었다. 수주간에 걸친 부신피질호르몬치료후 임상적, 생리학적, 그리고 방사선검사에서 많은 호전을 보였다. 이에 우리는 개흉술후 발생될 수 있는 급성호흡부전증에서 BOOP도 그 원인이 될 수 있음을 알았다. 이 경우 부신피질호르몬치료로 좋은 효과를 얻을 수 있으므로 개흉술후 발생되는 급성호 흡부전의 경우 가능한 조속히 조직검사를 시행할 팔요가 있음을 알 수 있었다.

• Journal of Korean Neurosurgical Society
• /
• 제40권4호
• /
• pp.217-226
• /
• 2006

Malignant gliomas are the most common type of primary brain tumor and are in great need of novel therapeutic approaches. Advances in treatment have been very modest, significant improvement in survival has been lacking for many decades, and prognosis remains dismal. Despite "gross total" surgical resections and currently available radio-chemotherapy, malignant gliomas inevitably recur due to reservoirs of notoriously invasive tumor cells that infiltrate adjacent and non-adjacent areas of normal brain parenchyma. In principle, the immune system is uniquely qualified to recognize and target these infiltrative pockets of tumors cells, which have generally eluded conventional treatment approaches, In the span of the last 10 years, our understanding of the cancer-immune system relationship has increased exponentially; and yet we are only beginning to tease apart the intricacies of the central nervous system and immune cell interactions. This article reviews the complex associations of the immune system with brain tumors. We provide an overview of currently available treatment options for malignant gliomas, existing gaps in our knowledge of brain tumor immunology, and strategies that might be exploited for improved design of "custom immunotherapeutics." We will also examine major new immunotherapy approaches that are being actively investigated to treat patients with malignant glioma, and identify some current and future research priorities in this area.

• Clinical and Experimental Pediatrics
• /
• 제45권4호
• /
• pp.529-534
• /
• 2002

저자들은 1개월 전부터 시작된 호흡 곤란과 마른 기침이 주증상인 10세 된 여아에서 조직학적 소견에서 비특이성 간질성 폐렴으로 진단된 1례를 보고하는 바이다.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제29권2호
• /
• pp.140-144
• /
• 2003

Ameloblastoma is cytologically a benign tumor, but is clinically characterized by infiltrative growth and high recurrency. The criteria for surgical treatment of ameloblastoma has not yet established and it is generally accepted that ameloblastoma be treated differently based on clinical types. The purpose of this paper is to consider effectiveness of enucleation in large-sized intraosseous ameloblastoma that has treated more frequently by radical treatment. 39 cases of the intraosseous ameloblastomas were treated by enucleation in the department of oral and maxillofacial surgery of Yonsei University, dental college from February 1990 to January 2001. 25 cases were selected because they were large in size that could produce facial disfigurement or pathologic fracture of jaws. They were radiographically characterized by the cortical bone that was expanded or eroded locally and histopathologically by 19 solid ameloblastomas and 6 intramural type of unicystic ameloblastomas. Among the 25 cases, 4 cases - 3 solid ameloblastomas and 1 intramural type of ameloblastoma - recurred. Recurrence rate was 16%. The compact bone which is not invaded by ameloblastoma was used as surgical margin of enucleation with accompanying chemical cauterization for killing the residual tumor cells. This may have been the reason for the low recurrence rate. So, it is considered that enucleation and long-term follow-up enable the large-sized intraosseous ameloblastomas that were characterized by almost destroyed cancellous bone and expanded or discontinued cortical bone to treat minimizing facial disfigurement and masticatory dysfunction and sociopsychological impact produced by radical treatment. I recommend that the large-sized intraosseous ameloblastomas without involvement to the surrounding soft tissues be first treated by enucleation.

• Tuberculosis and Respiratory Diseases
• /
• 제78권3호
• /
• pp.267-271
• /
• 2015

Desmoid tumors are rare soft tissue tumors considered to have locally infiltrative features without distant metastasis until now. Although they are most commonly intraabdominal, very few cases have extra-abdominal locations. The origin of intrathoracic desmoid tumors is predominantly the chest wall with occasional involvement of pleura. True intrathoracic primary desmoid tumors with no involvement of the chest wall or pleura are extremely rare. We recently experienced a case of true intrathoracic desmoid tumor presenting as multiple lung nodules at 13 years after resection of a previous intraabdominal desmoid tumor.

• Nuclear Medicine and Molecular Imaging
• /
• 제42권sup1호
• /
• pp.66-70
• /
• 2008

Reports about FDG PET in biliary tumor are limited and there are almost no reports regarding its efficacy. Biliary tumor is divided to intrahepatic and extrahepatic bile duct cancer, and intrahepatic bile duct cancer can be further divided to peripheral type which occurs at lobular duct and hilar type which occurs at hepatic hilum. Surgical resection is the only curative method for bile duct tumor, and accurate staging plays an important role in deciding treatment modality. Among intrahepatic bile duct tumors, peripheral type and hilar type have the same histological characteristics, but different clinical manifestations and tumor growth pattern. On PET image, FDG uptake is also different between peripheral type and hilar type. Most of the former shows high FDG uptake at primary and metastasis site so it is very useful for determining stage and changing treatment plans. However, the later is diversified among low uptake and very high uptake. The FDG uptake pattern of hilar type is similar to that of extrahepatic bile duct cancer, and mucinous component is an important factor, which affects FOG uptake. When tumor cells are scattered in desmoplatsic stroma, then FDG uptake is low as well. In contrast, when FDG uptake is high, it is likely to be tubular type which has high tumor density. Tumor growth pattern also affects FDG uptake. Nodular type mostly takes higher FDG compared to infiltrative type. There are many cases where benign inflammatory diseases take high FDG that PET alone can not distinguish malignant lesion from benign lesion. In conclusion, studies about PET using FDG are still limited. Thus, it is hard to make accurate conclusion about the roles of PET or PET/CT in biliary cancers, but peripheral type intrahepatic bile duct cancers and mass forming hilar and extrahepatic bile duct cancers appear to be good indications performing FDG PET or PET/CT.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권3호
• /
• pp.1553-1564
• /
• 2016

Identification of novel therapeutics in glioblastoma remains crucial due to the devastating and infiltrative capacity of this malignancy. The current study was aimed to appraise effect of arsenic trioxide (ATO) in U87MG cells. The results demonstrated that ATO induced apoptosis and impeded proliferation of U87MG cells in a dose-dependent manner and also inhibited classical NF-${\kappa}B$ signaling pathway. ATO further upregulated expression of Bax as an important proapoptotic target of NF-${\kappa}B$ and also inhibited mRNA expression of survivin, c-Myc and hTERT and suppressed telomerase activity. Moreover, ATO significantly increased adhesion of U87MG cells and also diminished transcription of NF-${\kappa}B$ down-stream targets involved in cell migration and invasion, including cathepsin B, uPA, MMP-2, MMP-9 and MMP-14 and suppressed proteolytic activity of cathepsin B, MMP-2 and MMP-9, demonstrating a possible mechanism of ATO effect on a well-known signaling in glioblastoma dissemination. Taken together, here we suggest that ATO inhibits survival and invasion of U87MG cells possibly through NF-${\kappa}B$-mediated inhibition of survivin and telomerase activity and NF-${\kappa}B$-dependent suppression of cathepsin B, MMP-2 and MMP-9.

• Journal of Yeungnam Medical Science
• /
• 제29권1호
• /
• pp.42-44
• /
• 2012

Plasma cell myelomas generally manifest as bone or soft-tissue tumors with variable mass effects, pain, and infiltrative behavior. Extramedullary involvement occurs most commonly in the spleen, liver, lymph nodes, and kidneys, but intracranial involvement in plasma cell myeloma is a rare extramedullary manifestation. These authors recently encountered a case of intracranial involvement of plasma cell myeloma. A 69-year-old man was hospitalized for headache and mental changes. Brain CT showed subdural hemorrhage caused by plasma cell myeloma. Plasma cell myeloma with intracranial involvement has poor prognosis, and the patient in this case died from acute complications, such as subdural hemorrhage. Based on this case report, it is suggested that more effective treatment regimens of plasma cell myeloma with intracranial involvement be developed. Moreover, a screening method and decision on the appropriate time for intracranial involvement are needed for plasma cell myeloma patients.